Xylazine addiction treatment that addresses the wounds, the withdrawal, and what drove the use.
Xylazine, known as tranq or tranq dope, is an animal sedative increasingly found in the illicit drug supply alongside fentanyl. Jintara's team in Chiang Mai coordinates medical detox, wound care, and trauma-informed therapy for people with xylazine-involved polysubstance use. For more on treatment options, see our drug addiction treatment overview.
- 24/7 awake nursing with structured vital sign monitoring throughout detox
- Wound care coordination with Bangkok Hospital Chiang Mai and RAM Hospital
- Psychiatrist-led opioid detox protocol adapted for xylazine-fentanyl polysubstance cases
- Trauma-informed therapy from day one, running in parallel with medical stabilisation
Fully Licensed Facility
NIDA Research: Xylazine
Xylazine is a non-opioid veterinary alpha-2 adrenergic agonist increasingly identified as an adulterant in illicit fentanyl supplies across North America, Australia, and parts of Europe. It is not an opioid and does not act on opioid receptors, which means naloxone cannot reverse its sedative effects.
Source: NIDA. Xylazine Research Overview
Xylazine Is a Veterinary Sedative Now Found Across the Illicit Fentanyl Supply.
Xylazine is a veterinary sedative now found as an adulterant in illicit fentanyl supplies. It has been identified in drug markets across North America, Australia, and parts of Europe and in most cases people using it do not know it is present. It is not an opioid. It does not act on opioid receptors. Illicit suppliers use it to extend the duration and reduce the cost of fentanyl. At street level it is called tranq, tranq dope, or simply the mix.
- Deeper sedation than fentanyl alone: The alpha-2 mechanism produces deep sedation that outlasts fentanyl by several hours. Someone who receives naloxone after a xylazine-fentanyl overdose may briefly rouse, then fall back into sedation as naloxone wears off.
- Undetected in most toxicology panels: Standard urine drug screens do not test for xylazine. People using it are often unaware it is in their supply, and clinicians unfamiliar with the presentation may not recognise the extended sedation as xylazine involvement.
- A specialist clinical presentation: Clients presenting with a history of xylazine-involved use require assessment protocols that go beyond standard opioid admission, with additional attention to wound status, nutritional state, and sedation history.
People with xylazine-involved dependence are assessed at Jintara using the same intake structure applied to opioid addiction treatment cases, with the clinical plan adapted from the first hour to reflect the xylazine-specific pharmacology.
NCBI: Xylazine-Associated Skin Wounds
Xylazine causes severe necrotic ulcers at and away from injection sites through vasoconstriction and tissue hypoxia rather than through infection alone. The vasoconstrictive effect can affect tissue distant from the injection site. Wounds can progress to involve deep tissue layers and become infected with resistant organisms including MRSA.
Xylazine Causes Necrotic Skin Wounds Through a Mechanism Unlike Standard Injection Site Reactions.
Xylazine causes severe skin wounds and necrotic ulcers at and away from injection sites through vasoconstriction and tissue hypoxia rather than through infection alone. The alpha-2 mechanism constricts local blood vessels, cutting oxygen supply to surrounding tissue. The result is progressive necrosis that can extend over a large surface area and reach deep tissue layers. This is distinct from the local infection seen with standard injection site reactions.
- Distant wound sites: Wounds can appear at sites distant from the injection point because xylazine redistributes in tissue and its vasoconstrictive effect is not limited to the puncture location.
- Infection risk: Untreated wounds can become infected with MRSA or develop into sepsis-level complications. A residential setting without wound care capacity is not appropriate for many xylazine-involved cases.
- Intake wound evaluation: Clients presenting with active wounds are evaluated on arrival. Cases requiring specialist wound care are referred to Bangkok Hospital Chiang Mai or RAM Hospital, both confirmed clinical partners.
Wound assessment is built into the intake process at Jintara. Medical detox management is coordinated alongside wound evaluation so that the clinical team has a full picture of the client's health status from day one.
CDC Health Alert Network: Xylazine
Naloxone reverses the opioid component of a xylazine-fentanyl overdose but cannot reverse xylazine sedation because xylazine acts on alpha-2 adrenergic receptors, not opioid receptors. Respiratory depression can persist even after a full naloxone dose. Emergency services must be prepared for repeated or ongoing sedation.
Naloxone Reverses the Opioid Component of a Xylazine Overdose but Cannot Reverse Xylazine Sedation.
Naloxone reverses the opioid component of a xylazine-fentanyl overdose but leaves the xylazine sedation in place. This means respiratory depression can persist even after a naloxone dose. This is a pharmacological property of xylazine as a non-opioid: it binds alpha-2 adrenergic receptors, not mu-opioid receptors, so naloxone has no mechanism to act on it.
- Risk of recurrent sedation: A person who has been given naloxone and appears to rouse may relapse into sedation within minutes. Rescue services unfamiliar with xylazine may interpret this as a failed naloxone dose and administer more, which does nothing for the ongoing xylazine sedation.
- Supportive care is essential: Close monitoring, supportive airway management, and transport to an emergency department are essential when xylazine is suspected, regardless of naloxone response.
- Implications for planned admission: For people seeking planned admission to treatment, understanding this pharmacology is important for the pre-admission conversation. The intake team asks directly about xylazine exposure so that the medical detox plan accounts for the sedation profile from the outset.
People considering treatment can contact the Jintara admissions team to discuss their specific situation before committing to a date.
NCBI: Xylazine Withdrawal Symptoms
Xylazine withdrawal does not cause seizures attributable to xylazine itself. The primary withdrawal symptoms are severe anxiety, agitation, insomnia, intense cravings, and psychological distress. When xylazine has been used alongside fentanyl, the opioid withdrawal component is the medical priority and responds to standard opioid taper protocols.
Xylazine Withdrawal Is Psychologically Intense but Does Not Carry the Same Physical Danger as Alcohol or Benzodiazepine Withdrawal.
Xylazine withdrawal is psychologically intense but is not medically dangerous in the same way that alcohol or benzodiazepine withdrawal can be. There is no seizure risk attributed to xylazine itself. The dominant symptoms are severe anxiety, agitation, intense cravings, insomnia, and a sense of dread that clients describe as among the most distressing experiences they have been through.
- Opioid withdrawal runs alongside: When xylazine has been used alongside fentanyl, which is the most common presentation, the opioid withdrawal component is typically the medical priority. Opioid withdrawal symptoms respond to a structured taper protocol overseen by the psychiatrist.
- Therapy from the stabilisation phase: Jintara's therapy team engages clients during the stabilisation phase rather than waiting until withdrawal is complete. Distress tolerance skills are introduced early to help clients manage the psychological intensity of the first days.
- A manageable process with clinical support: Clients who understand what to expect in the first days are better positioned to move through withdrawal without the additional distress of uncertainty. The nursing team explains the likely progression on the first night.
Distress tolerance and the broader treatment program at Jintara runs across the full stay for all clients, including those managing the psychological effects of xylazine withdrawal alongside opioid detox.
CDC MMWR: Xylazine in Drug Markets
Xylazine is predominantly encountered as an adulterant in illicit fentanyl rather than as a primary drug of use. Most people who present with xylazine-related harm were unaware xylazine was in their supply. Treatment planning must address the fentanyl dependence as the primary driver of physical addiction while also managing the xylazine-specific harms.
Source: CDC MMWR Vol.72 No.21. Xylazine in the US Drug Supply
Xylazine Is Most Commonly Encountered as an Adulterant in Illicit Fentanyl Rather Than as a Standalone Drug.
Xylazine is most commonly encountered as an adulterant in illicit fentanyl rather than as a standalone drug of use. Most people who present with xylazine-related harm are fentanyl-dependent and were unaware that xylazine was in their supply. Treatment planning must account for the fentanyl dependence as the primary driver of physical addiction while addressing the xylazine-specific harms.
- Fentanyl dependence is the medical focus: Fentanyl is 50 to 100 times more potent than morphine. Physical dependence develops rapidly, and the illicit supply is uncontrolled in dosing, making overdose risk very high.
- Xylazine compounds overdose risk: Xylazine compounds the overdose risk by extending sedation beyond the naloxone reversal window. This combination makes the xylazine-fentanyl presentation one of the most clinically complex currently seen in addiction medicine.
- Coordinated medical response required: The combination of high-potency opioid dependence and an adulterant that defeats standard overdose reversal requires coordinated medical, nursing, and psychiatric oversight from arrival.
Beyond Skin Wounds, Xylazine Causes Cardiovascular and Respiratory Effects That Require Medical Monitoring.
Beyond skin wounds, xylazine use causes respiratory depression, bradycardia, and hypotension that require medical monitoring and can become dangerous during acute intoxication or when combined with other central nervous system depressants. Many people presenting with long-term xylazine-involved fentanyl use are also nutritionally depleted, immunocompromised from chronic wound infections, and have untreated co-occurring mental health conditions.
- Day 2 full medical workup: Jintara's Day 2 medical review includes blood panel, liver and kidney function tests, ECG, and chest X-ray, completed at Bangkok Hospital Chiang Mai at Jintara's expense. This gives the clinical team a full baseline and allows early identification of infection markers, cardiac abnormalities, and nutritional deficiencies.
- Hospital-first when required: People with active infections, including wound infections, may require a hospital stay before transitioning to residential treatment. The no-compromise escalation policy applies: if there is any concern about medical safety, the client goes to hospital.
- Co-occurring mental health assessment: Trauma and mental health conditions are common in the xylazine-involved population. The dual diagnosis assessment happens in the first days and shapes the therapy plan from the outset.
Complex cases involving xylazine often benefit from dual diagnosis treatment integrated into the plan from the outset, given the high rate of co-occurring trauma and mental health conditions in this population.
“We tell people what we specialise in, we tell them what we don't do, and we refer them to rehabs that might be a better fit. With xylazine cases, we are specific about what our team is prepared for and what requires a hospital step first.
Assessment at Jintara Asks Explicitly About Xylazine Exposure From the First Hour.
Assessment at Jintara begins with withdrawal symptom scoring, urine screening for multiple drug classes, and a clinical history that explicitly asks about xylazine exposure. The nurse team is trained to ask about the drug supply used, whether xylazine was suspected or confirmed in the supply, and whether the client has experienced wound complications or prolonged sedation after naloxone administration, all of which are indicators of xylazine involvement.
- CIWA-Ar for alcohol component: The CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, Revised) protocol is used for the alcohol component if relevant. Opioid withdrawal severity is assessed using standard clinical tools.
- Xylazine-specific clinical focus: Xylazine-specific assessment focuses on wound status, cardiovascular baseline, and sedation history. The combination of these assessments gives the psychiatrist what is needed to set the initial medication plan before the client goes to sleep on their first night.
- Continuous nursing documentation: Nurses in early detox check clients every one to two hours when the withdrawal severity score is high, with documentation passed between shifts so the care picture is continuous.
Clients are encouraged to ask questions during the first week of treatment. The nursing team explains what is expected in the coming days so clients do not interpret worsening symptoms as a sign that something is wrong.
Wound Care Coordination Requires Clinical Partnerships Beyond the Residential Setting.
Active necrotic wounds require specialist wound care that goes beyond what a residential rehab manages alone. At Jintara, clients presenting with xylazine-associated wounds are evaluated on arrival and referred to Bangkok Hospital Chiang Mai or RAM Hospital for wound assessment and management. Both hospitals are confirmed clinical partners for Jintara and are located in Chiang Mai, close to the residential centre.
- Correct sequencing, not a barrier: For clients with stable wounds that are being managed, residential treatment can proceed alongside scheduled wound care appointments. For clients with active infections, sepsis indicators, or deep tissue necrosis requiring surgical debridement, hospital admission is required before residential treatment begins. This is the correct clinical sequence.
- Ongoing wound monitoring: The small residential setting at Jintara, with a maximum of ten clients, means the nursing team has direct visibility over each client's wound status throughout the stay. Dressing changes and wound monitoring are incorporated into the care schedule.
- No-compromise escalation: The 24/7 awake nursing team documents any signs of wound progression and escalates to hospital if the wound condition changes. Escalation is unconditional when there is any concern about medical safety.
The facilities at Jintara are designed for small-cohort clinical care. The size of the residential group means the nursing team is never spread thin across more clients than it can monitor closely.
Medical Detox for Xylazine-Fentanyl Cases Is Managed Through the Opioid Taper Protocol With Xylazine-Specific Adjustments.
Medical detox for xylazine-fentanyl polysubstance cases is led by the psychiatrist and managed through the opioid taper protocol, with specific adjustments for the sedation profile and cardiovascular effects of xylazine. Because xylazine is not an opioid, there is no pharmacological taper for the xylazine component. The opioid dependence is the primary focus of medication management.
- Methadone or clonidine-supported taper: For opioid withdrawal, the approach at Jintara is individualised and discussed between the client and the psychiatrist. Methadone taper is the most commonly used route for clients with significant opioid dependence. Some clients prefer to manage withdrawal with clonidine and benzodiazepine support as needed, without opioid substitution. The choice is made collaboratively.
- No standard post-detox maintenance MAT: Jintara does not offer naltrexone, acamprosate, or post-detox maintenance medication as a standard protocol. The treatment focus is residential therapy across the full program duration.
- Continuous vital sign monitoring: Vital sign monitoring, medication administration under the psychiatrist's plan, and symptom scoring are all documented continuously across shifts by the nursing team.
The nursing team at Jintara is led through each phase of the clinical plan by Lertkhwan Sukpia, Head Nurse, who oversees intake handover, daily symptom documentation, and discharge briefing for each client.
NIDA: Trauma and Addiction
Research consistently shows that approximately 70 to 90 percent of people presenting for addiction treatment have a significant trauma history. In xylazine-involved cases, the social circumstances driving use are often acute: homelessness, violence, extreme poverty, or a harm reduction context where xylazine entered the supply without warning.
Source: NIDA. Drugs, Brains, and Behavior: The Science of Addiction
Trauma-Informed Therapy Begins Alongside Medical Stabilisation, Not After It.
Xylazine use almost always accompanies severe trauma, social disruption, and circumstances that treatment must address directly if recovery is to hold. Jintara's therapy starts in parallel with detox, not after it. The first therapeutic contact is supportive and stabilising: explaining what to expect in the coming days, reducing fear of the withdrawal process, and establishing a therapeutic relationship before the harder clinical work begins.
- EMDR after medical stabilisation: For clients staying eight weeks or longer, EMDR therapy is introduced after medical stabilisation, working with trauma that underlies the use pattern. EMDRIA-certified therapist Denise O'Leary leads this work and has extensive experience with the trauma-addiction connection.
- Individual and group therapy throughout: Individual and group therapy run across the full stay for all clients, covering distress tolerance, relapse prevention, and life redesign.
- Aftercare planning built in: Aftercare planning is built into the final weeks of treatment and includes a written plan the client leaves with. For clients with xylazine-involved use, the aftercare plan accounts for the ongoing harm reduction needs and community support structures available in the client's home location.
Denise O'Leary, Clinical Director and EMDRIA-certified therapist, leads the therapy team. Her work with the trauma-addiction connection is central to the treatment model at Jintara for all complex detox presentations.
Talk with Our Admissions Team
Common Questions About Xylazine Addiction Treatment in Thailand
Xylazine is a veterinary sedative used to sedate large animals. It has entered the illicit drug supply predominantly as an adulterant added to fentanyl by suppliers. It is not sought by most people using it. The main reasons for its addition are cost reduction and extended duration of the sedative effect. Most people exposed to it have no idea it is in their supply.
Xylazine causes vasoconstriction, cutting off blood supply to local tissue. This produces necrosis, or tissue death, at and away from injection sites. The wounds can be large, deep, and slow to heal. They can become infected with resistant bacteria including MRSA. Unlike standard injection site infections, the wound mechanism is pharmacological rather than primarily infectious.
Xylazine is not an opioid, so it does not cause the same withdrawal syndrome. Xylazine withdrawal produces severe psychological symptoms: intense anxiety, agitation, insomnia, and cravings. It is not life-threatening in itself. When xylazine has been used with fentanyl, the opioid withdrawal component runs alongside and is typically the medical priority during detox.
Yes. Xylazine causes respiratory depression, bradycardia, and prolonged sedation, each of which can be fatal. The risk is compounded when xylazine is combined with fentanyl, because both substances depress the central nervous system. Overdose is a serious risk, particularly because the sedation outlasts naloxone reversal.
Naloxone works by blocking opioid receptors. Xylazine acts on alpha-2 adrenergic receptors, which naloxone does not affect. When naloxone is given for a xylazine-fentanyl overdose, it reverses the fentanyl component and the person may rouse briefly, but the xylazine sedation continues. Respiratory depression can persist even after a full naloxone dose.
Beyond skin wounds, long-term xylazine use is associated with cardiovascular strain, nutritional depletion, immunosuppression from chronic infections, and the cumulative respiratory effects of repeated sedation. Many people presenting with xylazine involvement also have untreated infections, low body weight, and mental health conditions that have not been assessed or treated.
Clients presenting with active wounds are assessed on arrival. Cases requiring specialist wound care are referred to Bangkok Hospital Chiang Mai or RAM Hospital, both confirmed clinical partners. Clients with stable wounds can begin residential treatment while continuing scheduled wound care. Cases with active infection or deep tissue involvement may require a hospital stay first.
The opioid withdrawal timeline drives the physical detox schedule. With a methadone taper protocol, the acute opioid withdrawal phase typically resolves over two to three weeks, with the taper continuing to zero over approximately three weeks. The psychological distress associated with xylazine exposure can persist beyond the acute medical phase and is addressed in ongoing therapy.
This depends on the wound status. Clients with stable, manageable wounds can be assessed for admission. Clients with severe active infections, sepsis indicators, or wounds requiring surgical care need to be medically stable before residential treatment begins. Darren Lockie reviews each case individually at the admissions stage. Contact Jintara to discuss a specific situation.
Once medical stabilisation is underway, individual and group therapy begin. Group therapy covers distress tolerance, trigger identification, relapse prevention, and life redesign. Individual therapy addresses the underlying drivers of use, including trauma. For clients staying eight weeks or longer, EMDR therapy is available after medical stabilisation. Aftercare planning is built into the final weeks of treatment. For further information, visit Jintara's homepage.